Journal of Hepatology
Volume 48, Issue 5 , Pages 774-779, May 2008

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study☆☆

  • Rubén Terg

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
    • Corresponding Author InformationCorresponding author. Fax: +54 11 4304 0006.
  • ,
  • Eduardo Fassio

      Affiliations

    • Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina
  • ,
  • Mónica Guevara

      Affiliations

    • Hospital Clinic Barcelona, Ciberehd, Ciber de Enfermedades Hepaticas y Digestivas, España, Universidad del Salvador, Buenos Aires, Argentina
    • Mónica Guevara is supported by a grant from Fondo de Investigación sanitaria 01/3045.
  • ,
  • Mariano Cartier

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Cristina Longo

      Affiliations

    • Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina
  • ,
  • Romina Lucero

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Cristina Landeira

      Affiliations

    • Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina
  • ,
  • Gustavo Romero

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Nora Dominguez

      Affiliations

    • Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina
  • ,
  • Alberto Muñoz

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Diana Levi

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Carlos Miguez

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina
  • ,
  • Raquel Abecasis

      Affiliations

    • Unidad de Hígado, Hospital de Gastroenterología “Dr. Bonorino Udaondo”, Sección Hepatología, Av. Caseros 2061, 1264 Buenos Aires, Argentina

Received 6 July 2007; received in revised form 27 December 2007; accepted 16 January 2008. published online 15 February 2008.

Associate Editor: C. Merkel

Background/Aims

Low protein concentration in ascitic fluid has been identified as a risk factor for spontaneous bacterial peritonitis (SBP). Until now, primary prophylaxis has not been recommended in these patients. The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP.

Methods

One hundred cirrhotic patients with <1.5g/dl of total protein in ascitic fluid were randomized prospectively, in a double blind fashion to receive ciprofloxacin 500mg/day (n=50) or placebo (n=50) for 12 months.

Results

Baseline data were similar in both groups. In the ciprofloxacin group, SBP occurred almost four times less frequently than in the placebo group but it was not statistically significant. The probability of survival at 12 months was significantly higher in patients receiving ciprofloxacin (86% versus 66%) (p<0.04). SBP and sepsis were the most frequent causes of death in the placebo group whereas gastrointestinal bleeding was responsible for the most deaths in the ciprofloxacin group. The probability of remaining free of bacterial infections was higher in patients receiving ciprofloxacin (80% versus 55%) (p=0.05).

Conclusions

Patients with cirrhosis and low protein concentration in ascitic fluid are candidates to receive long-term prophylaxis to reduce the risk of infections and improve survival.

Keywords: Spontaneous bacterial peritonitis, Primary prophylaxis, Ciprofloxacin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the drug involved either in the past or present and they did not receive funding from the manufacturers to carry out their research. Trial registration number is CCT-NAPN-16065.

☆☆ This study was supported by a grant from the Consejo de Investigación en Salud del Gobierno de la Ciudad de Buenos Aires.

PII: S0168-8278(08)00082-2

doi:10.1016/j.jhep.2008.01.024

Journal of Hepatology
Volume 48, Issue 5 , Pages 774-779, May 2008